Israel’s NeuroKaire (previously Genetika+ see here) has launched BrightKaire, the world’s first blood test to personalize depression treatment. It uses AI and stem cell tech to match patients with major depressive disorder (MDD) to effective medications. Approved in US and Israel.
Blood test identifies depression treatment
This entry was posted in Israel's Medical Achievements. Bookmark the permalink.